Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al
The three doses of GLP1/E led to a very significant reduction of body weight along the treatment period (Fig
17 The retrospective study found that subcutaneous semaglutide use was statistically significantly associated with the risk of developing NAION, no matter what the medications reason for use: patients with type 2 diabetes had a 4.28 HR compared to control (n=17 vs 6), while patients who used the medications for weight loss had a 7.64 HR compared to control (n=20 vs 3)
ABX Apps does not have a paid commercial relationship with Eli Lilly, Novo Nordisk, or any GLP-1 manufacturer
Can I transition to a regular dose if needed
Innovations, such as oral formulations and dual-target agonists, are reshaping competitive positioning